- Home
- TLS vs DCTH Comparison
TLS vs DCTH Comparison
Compare TLS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLS
- DCTH
- Stock Information
- Founded
- TLS 1969
- DCTH 1988
- Country
- TLS United States
- DCTH United States
- Employees
- TLS N/A
- DCTH N/A
- Industry
- TLS EDP Services
- DCTH Medical/Dental Instruments
- Sector
- TLS Technology
- DCTH Health Care
- Exchange
- TLS Nasdaq
- DCTH Nasdaq
- Market Cap
- TLS 199.9M
- DCTH 485.5M
- IPO Year
- TLS 2020
- DCTH N/A
- Fundamental
- Price
- TLS $3.22
- DCTH $12.50
- Analyst Decision
- TLS Buy
- DCTH Strong Buy
- Analyst Count
- TLS 6
- DCTH 4
- Target Price
- TLS $3.94
- DCTH $24.00
- AVG Volume (30 Days)
- TLS 936.5K
- DCTH 785.8K
- Earning Date
- TLS 08-08-2025
- DCTH 08-04-2025
- Dividend Yield
- TLS N/A
- DCTH N/A
- EPS Growth
- TLS N/A
- DCTH N/A
- EPS
- TLS N/A
- DCTH N/A
- Revenue
- TLS $109,269,000.00
- DCTH $53,850,000.00
- Revenue This Year
- TLS $35.76
- DCTH $155.42
- Revenue Next Year
- TLS $26.83
- DCTH $37.93
- P/E Ratio
- TLS N/A
- DCTH N/A
- Revenue Growth
- TLS N/A
- DCTH 1068.87
- 52 Week Low
- TLS $1.83
- DCTH $7.17
- 52 Week High
- TLS $4.82
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- TLS 70.55
- DCTH 33.81
- Support Level
- TLS $3.04
- DCTH $13.30
- Resistance Level
- TLS $3.30
- DCTH $14.15
- Average True Range (ATR)
- TLS 0.18
- DCTH 0.64
- MACD
- TLS 0.06
- DCTH -0.26
- Stochastic Oscillator
- TLS 94.62
- DCTH 8.28
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.